Your browser doesn't support javascript.
loading
Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency.
Fuchs, Sebastian; Rensing-Ehl, Anne; Pannicke, Ulrich; Lorenz, Myriam R; Fisch, Paul; Jeelall, Yogesh; Rohr, Jan; Speckmann, Carsten; Vraetz, Thomas; Farmand, Susan; Schmitt-Graeff, Annette; Krüger, Marcus; Strahm, Brigitte; Henneke, Philipp; Enders, Anselm; Horikawa, Keisuke; Goodnow, Christopher; Schwarz, Klaus; Ehl, Stephan.
Afiliación
  • Fuchs S; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany;
  • Rensing-Ehl A; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany;
  • Pannicke U; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany;
  • Lorenz MR; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany;
  • Fisch P; Institute of Pathology, University Medical Center Freiburg, Freiburg, Germany;
  • Jeelall Y; Department of Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia;
  • Rohr J; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Speckmann C; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Vraetz T; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Farmand S; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; and.
  • Schmitt-Graeff A; Institute of Pathology, University Medical Center Freiburg, Freiburg, Germany;
  • Krüger M; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Strahm B; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Henneke P; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
  • Enders A; Department of Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia;
  • Horikawa K; Department of Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia;
  • Goodnow C; Department of Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia;
  • Schwarz K; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany; Institute of Clinical Transfusion Medicine and Immungenetics Ulm, German Red Cross Blood Service Baden Württemberg-Hessen, Ulm, Germany.
  • Ehl S; Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, Freiburg, Germany; Center of Pediatric and Adolescent Medicine, University Medical Center and University of Freiburg, Freiburg, Germany;
Blood ; 126(14): 1658-69, 2015 Oct 01.
Article en En | MEDLINE | ID: mdl-26289640
Omenn syndrome (OS) is a severe immunodeficiency associated with erythroderma, lymphoproliferation, elevated IgE, and hyperactive oligoclonal T cells. A restricted T-cell repertoire caused by defective thymic T-cell development and selection, lymphopenia with homeostatic proliferation, and lack of regulatory T cells are considered key factors in OS pathogenesis. We report 2 siblings presenting with cytomegalovirus (CMV) and Pneumocystis jirovecii infections and recurrent sepsis; one developed all clinical features of OS. Both carried homozygous germline mutations in CARD11 (p.Cys150*), impairing NF-κB signaling and IL-2 production. A somatic second-site mutation reverting the stop codon to a missense mutation (p.Cys150Leu) was detected in tissue-infiltrating T cells of the OS patient. Expression of p.Cys150Leu in CARD11-deficient T cells largely reconstituted NF-κB signaling. The reversion likely occurred in a prethymic T-cell precursor, leading to a chimeric T-cell repertoire. We speculate that in our patient the functional advantage of the revertant T cells in the context of persistent CMV infection, combined with lack of regulatory T cells, may have been sufficient to favor OS. This first observation of OS in a patient with a T-cell activation defect suggests that severely defective T-cell development or homeostatic proliferation in a lymphopenic environment are not required for this severe immunopathology.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Activación de Linfocitos / Inmunodeficiencia Combinada Grave / Linfocitos T Reguladores / Proteínas Adaptadoras de Señalización CARD / Guanilato Ciclasa / Mutación Tipo de estudio: Risk_factors_studies Límite: Animals / Female / Humans / Infant / Male Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Activación de Linfocitos / Inmunodeficiencia Combinada Grave / Linfocitos T Reguladores / Proteínas Adaptadoras de Señalización CARD / Guanilato Ciclasa / Mutación Tipo de estudio: Risk_factors_studies Límite: Animals / Female / Humans / Infant / Male Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article